{"disease":{"id":"inclusion-body-myositis","name":"inclusion body myositis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00017914","title":"Adult and Juvenile Myositis","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT05721573","title":"A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Abcuro, Inc.","has_results":false},{"nct_id":"NCT01925209","title":"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02573467","title":"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":211,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02753530","title":"Study of Arimoclomol in Inclusion Body Myositis (IBM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"ZevraDenmark","has_results":true},{"nct_id":"NCT05046821","title":"Sporadic Inclusion Body Myositis Natural History Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT04049097","title":"Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":121,"lead_sponsor_name":"ZevraDenmark","has_results":true},{"nct_id":"NCT06605612","title":"Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":108,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT05272969","title":"Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":95,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT04907162","title":"Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT06536166","title":"Ruxolitinib Treatment in Inclusion Body Myositis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT00030212","title":"Immune Abnormalities in Sporadic Inclusion Body Myositis","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT07478172","title":"Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT07535996","title":"IBM Dietary Surveillance Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Manchester Metropolitan University","has_results":false},{"nct_id":"NCT02481453","title":"Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT01734369","title":"Environmental Risk Factors for Myositis in Military Personnel","phase":"","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT03633318","title":"Establishing Muscle Impedance Parameters With Electrical Impedance Myography","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05890833","title":"The Risk of Falls Index for Patients With Neuromuscular Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT07072676","title":"The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT04659031","title":"A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Abcuro, Inc.","has_results":false},{"nct_id":"NCT03440034","title":"Study of Pioglitazone in Sporadic Inclusion Body Myositis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06644482","title":"Exercise as Treatment for Patients With Inclusion Body Myositis","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT04421677","title":"Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT02250443","title":"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06479863","title":"Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Austin Neuromuscular Center","has_results":false},{"nct_id":"NCT04975841","title":"Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT03299335","title":"Molecular Profile of the Evolution of Inclusion Body Myositis","phase":"NA","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT03710941","title":"Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}